TOP TEN perturbations for 39256_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39256_at
Selected probe(set): 227261_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39256_at (227261_at) across 6674 perturbations tested by GENEVESTIGATOR:
NCI-H358 / HCC827
Relative Expression (log2-ratio):4.959376Number of Samples:6 / 6
Experimental | NCI-H358 |
Human bronchioloalveolar carcinoma derived cell line. Synonyms:H358; H-358 Cellosaurus code: | |
Control | HCC827 |
Human primary cancer cell line derived from the lung of a patient with non-small-cell lung cancer. Synonyms:HCC-827; HCC0827 Cellosaurus code: |
HCC827 / A-549
Relative Expression (log2-ratio):-4.785188Number of Samples:6 / 6
Experimental | HCC827 |
Human primary cancer cell line derived from the lung of a patient with non-small-cell lung cancer. Synonyms:HCC-827; HCC0827 Cellosaurus code: | |
Control | A-549 |
Human primary cancer cell line derived from the lung of a patient with carcinoma. Synonyms:A 549; A549; NCI-A549; A549/ATCC; hA549 Cellosaurus code: |
lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary) / lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Relative Expression (log2-ratio):4.3517036Number of Samples:4 / 2
Experimental | lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary pseudosarcomatous carcinoma of the lung (subcutaneously implanted). | |
Control | lung cancer study 1 (PDX; non-small cell carcinoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted). |
lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; basaloid carcinoma; primary)
Relative Expression (log2-ratio):-4.3508835Number of Samples:2 / 3
Experimental | lung cancer study 1 (PDX; non-small cell carcinoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted). | |
Control | lung cancer study 1 (PDX; basaloid carcinoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted). |
zalypsis study 1 / untreated MM1S cell sample
Relative Expression (log2-ratio):-4.293043Number of Samples:2 / 2
Experimental | zalypsis study 1 |
MM1S multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:--- | |
Control | untreated MM1S cell sample |
MM1S multiple myeloma cells untreated. |
cyclophosphamide study 6 (8155 uM; hES-Heps) / vehicle (DMSO) treated hES-Heps cell sample
Relative Expression (log2-ratio):-3.8902721Number of Samples:3 / 8
Experimental | cyclophosphamide study 6 (8155 uM; hES-Heps) |
hES-Heps cells exposed to 8155 uM cyclophosphamide (dissolved in 0.5% v/v DMSO) for 72 hours. Chemical was added at day 22 of differentiation. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code: | |
Control | vehicle (DMSO) treated hES-Heps cell sample |
hES-Heps cells treated with vehicle (DMSO 0.5% v/v) for 72 hours. Vehicle was added at day 22 of differentiation. |
CML study 1 / B-CLL study 5
Relative Expression (log2-ratio):-3.8561678Number of Samples:75 / 441
Experimental | CML study 1 |
Bone marrow samples of patients with chronic myeloid leukemia (CML). | |
Control | B-CLL study 5 |
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL). |
ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) / ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)
Relative Expression (log2-ratio):3.7557383Number of Samples:13 / 2
Experimental | ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary serous cystadenocarcinoma, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted). |
AsPC-1 / BxPC-3
Relative Expression (log2-ratio):-3.6865835Number of Samples:3 / 3
Experimental | AsPC-1 |
Human xenograft derived metastatic cancer cell line derived from mouse xenografts initiated with metastatic cells from the ascites derived from a 62 years old female Caucasian patient with pancreatic adenocarcinoma. Synonyms:AsPc-1; Aspc-1; ASPC-1; As-PC1; ASPC1; AsPC1; Aspc1; AsPc1 Cellosaurus code: | |
Control | BxPC-3 |
Human pancreatic adenocarcinoma cell line derived from a 61 years old female patient. Synonyms:BxPc-3; BXPC-3; Bx-PC3; BXPC3; BxPC3; BxPc3 Cellosaurus code: |
renal cell carcinoma study 6 (chromophobe type) / normal kidney tissue (fetal)
Relative Expression (log2-ratio):-3.5296965Number of Samples:4 / 2
Experimental | renal cell carcinoma study 6 (chromophobe type) |
Tumor tissue samples from the kidney of patients with chromophobe renal cell carcinoma (cRCC). | |
Control | normal kidney tissue (fetal) |
Normal fetal kidney tissue samples. |